Sutent tops kidney-cancer drug scrips

Here's a quiz for you: Which kidney cancer drug is prescribed most for new patients? It's one of four newish drugs that came onto the renal-disease scene in recent years and quickly captured the market: Sutent from Pfizer, Nexavar from Bayer and Onyx Pharmaceuticals, Torisel from Wyeth, and Avastin from Genetech and Roche.

If you said Sutent, you're right. The Pfizer drug is "showing the most promise" as a first-line therapy, according to a new report from Datamonitor. But ironically, the most-prescribed second-line treatment--Nexavar--may not be the most effective choice in patients who started out on Sutent, the report states. Both drugs, you see, work by inhibiting angiogenesis, or blood-vessel growth. Torisel, on the other hand, targets a protein that's vital to tumor growth, and it's the only one of the fourth that's proven to increase overall survival, not just progression-free survival.

Regardless, there's still lots of room for new renal-cancer remedies, Datamonitor concludes. Experts think that, like other cancers, renal cancer will respond best to drug combinations rather than individual treatments.

- see this release for more

Related Articles:
FDA approves Pfizer's Sutent for cancer. Report
Pfizer's cancer drug Sutent shows promise. Report
FDA approves Nexavar for kidney cancer. Report
Bayer, Onyx announce disappointing Nexavar results. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.